Disease |
|
|
|
|
|
PA444119
|
Eye diseases |
70/437 |
1.1E-11 |
2.3E-08 |
|
PA443521
|
Blindness |
36/96 |
3.4E-08 |
3.8E-05 |
|
PA443320
|
Amblyopia |
15/45 |
1.3E-07 |
9.5E-05 |
|
PA444117
|
Eye abnormalities |
32/189 |
1.3E-06 |
6.4E-04 |
|
PA445532
|
Retinal diseases |
42/285 |
1.4E-06 |
6.4E-04 |
|
PA445530
|
Retinal degeneration |
36/234 |
2.9E-06 |
1.1E-03 |
|
PA165108137 |
Retinitis NOS |
31/194 |
6.4E-06 |
2.0E-03 |
|
PA443989
|
Ectopia lentis |
7/13 |
7.5E-06 |
2.1E-03 |
|
PA445537
|
Retinitis pigmentosa |
31/197 |
8.8E-06 |
2.2E-03 |
|
PA447310
|
Vision disorders |
21/112 |
1.7E-05 |
3.8E-03 |
KEGG |
|
|
|
|
|
hsa05210 |
Colorectal cancer––Homo sapiens (human) |
18/62 |
8.0E-07 |
2.4E-04 |
|
hsa05213 |
Endometrial cancer––Homo sapiens (human) |
15/52 |
7.3E-06 |
8.5E-04 |
|
hsa05161 |
Hepatitis B––Homo sapiens (human) |
28/146 |
8.5E-06 |
8.5E-04 |
|
hsa05200 |
Pathways in cancer––Homo sapiens (human) |
56/397 |
1.2E-05 |
8.8E-04 |
|
hsa05203 |
Viral carcinogenesis––Homo sapiens (human) |
34/205 |
2.6E-05 |
1.5E-03 |
|
hsa01521 |
EGFR tyrosine kinase inhibitor resistance––Homo sapiens (human) |
18/81 |
4.7E-05 |
2.0E-03 |
|
hsa05230 |
Central carbon metabolism in cancer––Homo sapiens (human) |
16/67 |
4.9E-05 |
2.0E-03 |
|
hsa05215 |
Prostate cancer––Homo sapiens (human) |
19/89 |
5.3E-05 |
2.0E-03 |
|
hsa04915 |
Estrogen signaling pathway––Homo sapiens (human) |
20/100 |
9.0E-05 |
3.0E-03 |
|
hsa05222 |
Small cell lung cancer––Homo sapiens (human) |
18/86 |
1.1E-04 |
3.0E-03 |